
NYSEHealthcareDrug Manufacturers - General
Latest quote
$37.82
−$1.05 · -2.70%
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Previous close
$37.82
−$1.05 · -2.70%
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
99
Deep Value
Sentiment
52
Mixed
Risk
34
Moderate Risk
Momentum
45
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Day range
Current $37.82
52-week range
Current $37.82
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (DKK) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 309.06B DKK | 290.4B DKK | 232.26B DKK | 176.95B DKK | 140.8B DKK |
| Cost of goods sold | 58.79B DKK | 44.52B DKK | 35.77B DKK | 28.45B DKK | 23.66B DKK |
| Gross profit | 250.28B DKK | 245.88B DKK | 196.5B DKK | 148.51B DKK | 117.14B DKK |
| Research and development | 52.04B DKK | 48.06B DKK | 32.44B DKK | 24.05B DKK | 17.77B DKK |
| Selling, general, and administrative | 70.28B DKK | 67.38B DKK | 61.6B DKK | 50.68B DKK | 41.06B DKK |
| Operating expenses | 122.62B DKK | 117.54B DKK | 93.92B DKK | 73.7B DKK | 58.5B DKK |
| Interest income | 1.27B DKK | 1.84B DKK | 1.07B DKK | 239M DKK | 231M DKK |
| Interest expense | 4.21B DKK | 1.64B DKK | 542M DKK | 378M DKK | 289M DKK |
| Depreciation and amortization | 21.98B DKK | 19.11B DKK | 9.41B DKK | 7.36B DKK | 6.03B DKK |
| Operating income | 127.66B DKK | 128.34B DKK | 102.57B DKK | 74.81B DKK | 58.64B DKK |
| Net income | 102.43B DKK | 100.99B DKK | 83.68B DKK | 55.53B DKK | 47.76B DKK |
Company facts updated Nov 22, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$42.33
11.92% upsideCash distributions grouped by calendar year; partial years are marked.
$1.7269
2025 complete year+134.6% since 2021
2026 partial: $1.7966
$0.7362
2,021
$0.8001
2,022
$1.0285
2,023
$1.4462
2,024
$1.7269
2,025
$1.7966
2,026*
* Partial calendar year in the available dividend history.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Aug 17, 2026 | $0.5792Semi-Annual | Aug 17, 2026 | Aug 25, 2026 |
Dividend | Mar 30, 2026 | $1.2174Semi-Annual | Mar 30, 2026 | Apr 8, 2026 |
Dividend | Aug 18, 2025 | $0.5843Semi-Annual | Aug 18, 2025 | Aug 26, 2025 |
Dividend | Mar 31, 2025 | $1.1426Semi-Annual | Mar 31, 2025 | Apr 8, 2025 |
Dividend | Aug 16, 2024 | $0.5169Semi-Annual | Aug 16, 2024 | Aug 26, 2024 |
Dividend | Mar 22, 2024 | $0.9293Semi-Annual | Mar 25, 2024 | Apr 2, 2024 |
Ex-dividend Aug 17, 2026
$0.5792
Semi-Annual
Record Aug 17, 2026 · Payment Aug 25, 2026
Ex-dividend Mar 30, 2026
$1.2174
Semi-Annual
Record Mar 30, 2026 · Payment Apr 8, 2026
Ex-dividend Aug 18, 2025
$0.5843
Semi-Annual
Record Aug 18, 2025 · Payment Aug 26, 2025
Ex-dividend Mar 31, 2025
$1.1426
Semi-Annual
Record Mar 31, 2025 · Payment Apr 8, 2025
Ex-dividend Aug 16, 2024
$0.5169
Semi-Annual
Record Aug 16, 2024 · Payment Aug 26, 2024
Ex-dividend Mar 22, 2024
$0.9293
Semi-Annual
Record Mar 25, 2024 · Payment Apr 2, 2024
Funds reporting this stock among their holdings, ordered by reported position size.
Avantis International Equity ETFAVDE57.43M0.31%18.31B USD0.23%$82.46-2.61%
VanEck Pharmaceutical ETFPPH55.82M5.46%1.02B USD0.36%$114.85-0.09%
First Trust WCM International Equity ETFWCMI32.6M1.67%1.95B USD0.85%$16.58-3.44%
Fidelity Enhanced International ETFFENI32.21M0.28%11.63B USD0.28%$36.79-2.49%
Invesco International Dividend Achievers ETFPID17.11M2.00%847.17M USD0.53%$21.5455-0.80%
Hartford Multifactor Developed Markets (ex-US) ETFRODM11.53M0.71%1.61B USD0.29%$39.82-1.51%
Avantis International Large Cap Value ETFAVIV9.19M0.46%1.95B USD0.25%$74.07-2.39%
ActivePassive International Equity ETFAPIE7.93M0.78%1.02B USD0.45%$34.50-3.28%
Avantis International Equity ETFAVDE
VanEck Pharmaceutical ETFPPH
First Trust WCM International Equity ETFWCMI
Fidelity Enhanced International ETFFENI
Invesco International Dividend Achievers ETFPID
Hartford Multifactor Developed Markets (ex-US) ETFRODM
Avantis International Large Cap Value ETFAVIV
ActivePassive International Equity ETFAPIEAI-generated and delayed market data for informational and educational purposes only. Not investment advice.